Research Reels: Open Orphan - Challenging the Norm

In our latest note, we have looked at Challenge Studies, a small but growing segment of the Clinical Research Organisation service market, and analysed the prospects of Open Orphan - a market leader in this sub-category with decades of expertise, world-leading infrastructure, and a strong order book of blue-chip pharmaceutical customers. With consolidation in the sector creating scarcity, we argue that Open Orphan is well-positioned to capitalise as this market continues to evolve and is the best way for investors to play the theme.

This communication is for use only by a person or entity that qualifies as a "Professional Client" or "Eligible Counterparty" within the meaning of the FCA's rules. It is intended for use only by persons having professional experience in matters relating to investments. Any other person who receives this should not act on the contents. Disclaimer here